A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis

Exclusion Criteria

• •1. Subject who has Body Mass Index (BMI) \> 35 kg/m2
• •2. Subject judged by the investigator to have a history of clinically significant disease(s) (i.e., uncontrolled comorbid disease, kidney diseases, liver diseases, endocrine diseases, etc., but not limited to these diseases) that may affect the patient's participation in the study.
• •3. Subject who has any of following clinically significant diseases:
• •* Autoimmune diseases
• •* Paget's disease, ochronosis, acromegaly, hemochromatosis, or Wilson's disease
• •* Genetic diseases (hyperkinesia, collagen gene abnormality, etc.)
• •* Inflammatory joint disorders (e.g., rheumatoid inflammation)
• •* Infectious joint disorders (e.g., septic arthritis)
• •* Other joint disorders (e.g., gout, recurrent pseudogout, articular fracture, primary osteochondrosis, villonodular synovitis)
• •4. Subject who has any history of cancer and/or currently receiving treatment for a current cancer diagnosis.
• •5. Subject who is positive in pathogenic test (HIV, viral hepatitis, or syphilis)
• •6. Subject who has heart diseases (myocardial infarction, coronary artery bypass graft surgery, arrhythmia, or other serious heart diseases) or has history of heart diseases within 6 months prior to Screening
• •7. Subject who has received any intra-articular therapy in any joint within 6 months prior to Screening, or surgery on the relevant knee including articular endoscopic procedures within 6 months prior to Screening
• •8. Subject who has history of prolotherapy, or platelet rich plasma injection within 6 months prior to Screening
• •9. Subject who has received long-acting hyaluronic acid injection (e.g., Synvisc-One®, etc.) within 6 months prior to Screening
• •10. Subject who has history of stem cell therapy
• •11. Subject who has significant lab abnormalities for the following parameters (If the value is within 10% of the listed laboratory exclusion criterion value and the value is considered not to be clinically significant by the investigator, the subject can be considered for enrollment):
• •* Serum ALT and AST \> 2 x upper limit of normal
• •* Serum creatinine out of normal range
• •* PT/INR out of normal range
• •* Hemoglobin \< 10 g/dL for female subject and hemoglobin \< 11 g/dL for male subject
• •* Platelets out of normal range
• •12. Subject for whom the investigator judges the lipoaspiration can cause any problem
• •13. Subject who has history of local anesthetic allergy
• •14. Subject who has taken anti-inflammatory drugs (prescription and non-prescription NSAIDs), symptomatic slow acting drugs (glucosamine, chondroitin sulfate, diacerhein etc.), or oral steroids (prednisone etc.) within 14 days prior to Screening (however, those who undergo a 14-day wash-out period can participate.)
• •15. Subject who is an active drug/alcohol abuser
• •16. Pregnant or breast-feeding women, or women or men who are not using appropriate method of contraception (appropriate method includes hormones, bilateral tubal ligation, and barrier method with spermicide, and intra-uterine device for women and vasectomy and barrier method with spermicide for men; subjects should agree to use appropriate method)
• •17. Subject who is enrolled in any other clinical trials within 3 months from screening
• •18. Subject who received the COVID-19 vaccines within 1 week from Visit 2 (Lipoaspiration, baseline)
• •19. Subject who the principal investigator considers inappropriate for the study due to any other reasons than those listed above